

Cases from the Community: Investigators Discuss Emerging Research and Actual Patients with Gastroesophageal Cancers

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following regimens is being investigated as first-line therapy for patients with advanced hepatocellular carcinoma (HCC) in the ongoing Phase III LEAP-002 trial?
 - a. Nivolumab/lenvatinib
 - b. Pembrolizumab/cabozantinib
 - c. Atezolizumab/sorafenib
 - d. Pembrolizumab/lenvatinib
2. The ongoing MOUNTAINEER-02 trial is investigating which of the following HER2-directed regimens in combination with ramucirumab and paclitaxel for patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma?
 - a. Pertuzumab/tucatinib
 - b. Tucatinib/trastuzumab
 - c. Pertuzumab/trastuzumab
3. Which of the following adverse events is associated with the antibody-drug conjugate trastuzumab deruxtecan (T-DXd)?
 - a. QT interval prolongation
 - b. Pneumonitis
 - c. Dysgeusia
4. The Phase III TAGS study evaluating trifluridine/tipiracil (TAS-102) versus placebo in combination with best supportive care for patients with refractory metastatic gastric cancer demonstrated which of the following overall survival outcomes?
 - a. A significant improvement with TAS-102
 - b. No significant difference between the study arms